
Septerna Inc (SEPN) Stock Forecast & Price Target
Septerna Inc (SEPN) Analyst Ratings
Bulls say
Septerna is currently in the preclinical stage of development, with plans to enter the clinic with its lead candidate in 2027. The company maintains a strong financial position with over $500 million in cash, enough to fund operations until at least 2029. Recent updates on the company's pipeline have shown promising data, including a human half-life of approximately 3-4 days for their lead candidate SEP-479 and potential for their MRGPRX2 NAM, SEP-631, in multiple indications. With a diverse and robust pipeline and a strong cash position, investors should keep an eye on the potential for upside should SEP-479 continue to show positive results in upcoming trials.
Bears say
Septerna is a clinical-stage biotechnology company that operates in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. While its proprietary Native Complex Platform shows potential for GPCR therapies, the outlook for the company remains negative due to the lack of diverse product revenue and high risks associated with phase 1 trials, developmental milestones, and competition in target markets, resulting in a limited price objective of $60 per share by mid-2027.
This aggregate rating is based on analysts' research of Septerna Inc and is not a guaranteed prediction by Public.com or investment advice.
Septerna Inc (SEPN) Analyst Forecast & Price Prediction
Start investing in Septerna Inc (SEPN)
Order type
Buy in
Order amount
Est. shares
0 shares